Chinese Pharma Breakthroughs in Parkinson’s Disease Therapeutics: Cell and Gene Therapy Innovations Accelerate

　　【Pharmaceutical Network Industry DynamicsParkinson's disease is a common neurodegenerative disorder, with main symptoms including resting tremors, bradykinesia, and muscle rigidity. In recent years, with an in-depth understanding of the pathogenesis of Parkinson’s disease, new-generation drugs such as neuroprotective agents and gene therapies are being rapidly developed. Notably, in recent times, several Chinese pharmaceutical companies have made significant breakthroughs in the field of Parkinson’s disease treatment.
 

Recently, iRegene (Chengdu) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "iRegene") announced that its self-developed NouvNeu001 injection has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
 

RMAT is an accelerated approval pathway established by the United States in the 21st Century Cures Act in December 2016. It is specifically designed for regenerative medicine therapies, oriented towards significant clinical value, to facilitate their rapid market entry and address unmet medical needs. Four months ago, NouvNeu001 had just been granted FTD status by the FDA, and this RMAT designation once again demonstrates the FDA's high recognition of its clinical data.
 

It is reported that NouvNeu001 is the world's first iPSC-derived chemically induced universal dopaminergic neural precursor cell, capable of repairing dopaminergic neuron loss through cell replacement therapy, reversing disease progression, and demonstrating significant therapeutic potential. On December 16, 2025, a Phase I/III clinical study on the safety, tolerability, and efficacy of intraputamenal transplantation for the treatment of multiple system atrophy has also been initiated.
 

On November 24, Rotigotine Transdermal Patch (brand name: Lofiding), independently developed by Beijing Tide Pharmaceutical Co., Ltd., was officially approved for marketing by the National Medical Products Administration. It is indicated for the monotherapy of symptoms and signs of early idiopathic Parkinson's disease or combined with levodopa for use in all stages of the disease course. The once-daily patch administration improves medication adherence for patients with swallowing difficulties or cognitive impairment.
 

Rotigotine, as a non-ergot dopamine receptor agonist, avoids the first-pass effect of the liver through transdermal administration, achieving a stable blood concentration over 24 hours, effectively improving core symptoms such as "slowness, tremor, rigidity, and falls" in Parkinson's disease patients. Currently, this product has been included in multiple domestic and international guidelines, becoming a recommended initial treatment for early-onset Parkinson's disease.
 

On December 22, Zhongsheng Traceability (Guangzhou) Biotechnology Co., Ltd. / Anhui Zhongsheng Traceability Biotechnology Co., Ltd. initiated a Phase I/II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of NCR201 injection, derived from human-induced pluripotent stem cell-sourced dopaminergic neural precursor cells, for the treatment of Parkinson's disease (PD).
 

NCR201 Injection is a biological product. The primary objective of this trial is to evaluate the efficacy of NCR201 Injection in treating patients with Parkinson's disease (PD); the secondary objective is to assess the efficacy and safety of stereotactic intracerebral injection of NCR201 Injection for Parkinson's disease (PD) patients.
 

November 17: Shanghai Tianze Yuntai Biomedical Co., Ltd. announced that two of its self-developed gene therapy products for Parkinson's disease have received Fast Track Designation (FTD) from the U.S. FDA. Among them, the newly designated VGN-R08b is aimed at treating Parkinson's disease associated with GBA1 gene mutations (PD-GBA). The other product, VGN-R09b, targets primary Parkinson's disease and received FDA Fast Track Designation in June this year.
 

Overall, the current treatment of Parkinson's disease has entered a new era that emphasizes both fundamental and symptomatic treatments, with innovative technologies and improved solutions being developed simultaneously. Among these, the continuous breakthroughs by Chinese pharmaceutical companies in cutting-edge fields such as cell therapy and gene therapy signify that China has become an indispensable part of the global landscape for innovative Parkinson’s disease research and development. In the future, with the efforts of many Chinese pharmaceutical enterprises, patients with Parkinson’s disease will have access to more treatment options.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.